CCR5 antagonists are being tested in combination with the checkpoint inhibitors pembrolizumab and nivolumab, humanized monoclonal anti-PD-1 antibodies that block PD-1 on T cells, preventing their inactivation by PD-L1 expressed by cancer cells, TAMs, and CAFs. The gene discussed is CD274; the disease is cancer.